Photodynamic therapy: A new approach to prostate cancer

被引：29
作者：
Rolf Muschter
机构：
[1] Diakoniekrankenhaus Academic Teaching Hospital, Rotenburg
来源：
Current Urology Reports | 2003年 / 4卷 / 3期
关键词：
Hypericin; mTHPC; Photodynamic Therapy; Photofrin; Prostate Cancer;
D O I：
10.1007/s11934-003-0073-4
中图分类号：
学科分类号：
摘要：
Photodynamic therapy (PDT) is based on the concept that light irradiation can change an inert substance into an active one. In urology, hematoporphyrin derivative (HpD) and Photofrin (Axcan Scandipharm Inc., Birmingham, AL) are used most commonly as photosensitizing agents predominantly for the treatment of transitional cell carcinoma of the bladder. To investigate the basics for PDT of prostate cancer, several studies were performed on the optical characteristics of prostate tissue and prostate carcinoma tissue in vitro and in vivo and on the penetration depths of different laser wavelengths. Initial experimental studies to treat prostate cancer with PDT using HpD were done on Dunning tumors in rats. Combined with interstitial applicators, photodynamic therapy seems to have a great potential in the treatment of prostate carcinoma. However, it is an experimental treatment and even a preliminary evaluation will be possible only after the conclusion of clinical studies with the corresponding long-term results. © 2003, Current Science Inc.
引用
收藏
页码：221 / 228
页数：7
相关论文
共 51 条
  • [11] Kriegmair M., Baumgartner R., Knuchel R., Et al., Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence, J Urol, 155, pp. 105-110, (1996)
  • [12] Bedwell J., MacRobert A.J., Phillips D., Bown S.C., Fluorescence distribution and photodynamic effect of 5-aminolevulinic acid induced PPIX in the DMH rat colonic tumour model, Br J Cancer, 65, pp. 818-824, (1992)
  • [13] Arnfield M.R., Chapman J.D., Tulip J., Et al., Optical properties of experimental prostate tumors in vivo, Photochem Pathol, 57, pp. 306-311, (1993)
  • [14] Pantelides M.L., Whitehurst C., Moore I.V., Et al., Photodynamic therapy for localized prostatic cancer: light penetration in the human prostate gland, J Urol, 143, pp. 398-401, (1990)
  • [15] Whitehurst C., Pantelides M.L., Moore J.V., Et al., In vivo laser light distribution in human prostatic carcinoma, J Urol, 151, pp. 1411-1415, (1994)
  • [16] Lee L.K., Whitehurst C., Pantelides M.L., Moore J.V., In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland, Photochem Photobiol, 62, pp. 882-885, (1995)
  • [17] Lee L.K., Whitehurst M.L., Pantelides C., Moore J.V., An interstitial light assembly for photodynamic therapy in prostatic carcinoma, BJU Int, 84, pp. 821-826, (1999)
  • [18] Levy D.A., Schwartz J., Ostermeyer M., Et al., Transurethral in vivo optical properties of the human prostate gland, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems, pp. 329-334, (1996)
  • [19] Barajas O., Ballangrud A.M., Miller G.G., Et al., Monte Carlo modeling of angular radiance in tissue phantoms and human prostate: PDT light dosimetry, Phys Med Biol, 42, pp. 1675-1687, (1997)
  • [20] Chen Q., Hetzel F.W., Laser dosimetry studies in the prostate, J Clin Laser Med Surg, 16, pp. 9-12, (1998)
123456